Global Capecitabine Market Insights, Forecast to 2025
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Capecitabine is a prescription medication used to treat breast cancer and cancer of the colon or rectum. Capecitabine belongs to a group of drugs called antimetabolites which work by interfering with DNA production, stopping cells from multiplying. The medication comes in tablet form and is usually taken twice daily, within 30 minutes after the end of a meal. The proportion of breast cancer with Handle in 2016 is about 40%, and the proportion of colorectal cancer in 2016 is about 31.94%.
Cancer clinical treatment projects have led to the increasing demand for Capecitabine. Increasing Cancer incidence across the globe, especially in the Asia-Pacific is another major factor, driving the growth of the Capecitabine market during the forecast period.
The global Capecitabine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Capecitabine market based on company, product type, end user and key regions.
This report studies the global market size of Capecitabine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Capecitabine in these regions.
This research report categorizes the global Capecitabine market by top players/brands, region, type and end user. This report also studies the global Capecitabine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Market size by Product
500 mg
150 mg
Market size by End User
Breast Cancer
Colorectal Cancer
Stomach Cancer
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Capecitabine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Capecitabine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Capecitabine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Capecitabine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Capecitabine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Kg). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Capecitabine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Capecitabine is a prescription medication used to treat breast cancer and cancer of the colon or rectum. Capecitabine belongs to a group of drugs called antimetabolites which work by interfering with DNA production, stopping cells from multiplying. The medication comes in tablet form and is usually taken twice daily, within 30 minutes after the end of a meal. The proportion of breast cancer with Handle in 2016 is about 40%, and the proportion of colorectal cancer in 2016 is about 31.94%.
Cancer clinical treatment projects have led to the increasing demand for Capecitabine. Increasing Cancer incidence across the globe, especially in the Asia-Pacific is another major factor, driving the growth of the Capecitabine market during the forecast period.
The global Capecitabine market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Capecitabine market based on company, product type, end user and key regions.
This report studies the global market size of Capecitabine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Capecitabine in these regions.
This research report categorizes the global Capecitabine market by top players/brands, region, type and end user. This report also studies the global Capecitabine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Market size by Product
500 mg
150 mg
Market size by End User
Breast Cancer
Colorectal Cancer
Stomach Cancer
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Capecitabine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Capecitabine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Capecitabine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Capecitabine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Capecitabine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Kg). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Capecitabine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
